Reply of the Authors: Risks Versus Benefits of Valproic Acid?
Sun‐Wei Guo,Xishi Liu
DOI: https://doi.org/10.1016/j.fertnstert.2008.05.001
IF: 6.7
2008-01-01
Fertility and Sterility
Abstract:Reply of the Authors We thank Drs. Chandrareddy and Muneyyirchi-Delale for their interest in our paper (1Liu X. Guo S.W. A pilot study on the off-label use of valproic acid to treat adenomyosis.Fertil Steril. 2008; 89: 246-250Abstract Full Text Full Text PDF PubMed Scopus (55) Google Scholar); they raise several interesting issues. Citing the literature suggesting that valproic acid (VPA) may cause hyperandrogenism, they questioned the appropriateness of using VPA for treating adenomyosis. Yet they ignored an important take-home message from the very same paper by Flück et al. that “[n]one of the tested AEDs influenced 3βHSDII or P450c17 activities at concentrations normally used in AED therapy” (emphasis added; AED = antiepileptic drugs, including VPA). Apparently, Drs. Chandrareddy and Muneyyirchi-Delale were unaware of the adage by the father of modern toxicology, “only dose makes the poison.” As with dose, the duration of medication can also make a difference. The two studies cited by Drs. Chandrareddy and Muneyyirchi-Delale actually examined women taking VPA for a period of time (≥2 years) much longer than 3 months, as we used. Their equation of hyperandrogenism, which was not observed in our study, with polycystic ovary syndrome is also at odds with the Rotterdam diagnostic criteria. Drs. Chandrareddy and Muneyyirchi-Delale were concerned about the lengthening of menstrual cycle in two out of three patients taking VPA, yet they were unfazed by oligomenorrhea, spotting, and other, sometimes more serious, side effects that are fairly common in other medications, including the levonorgestrel-releasing intrauterine system (2Bragheto A.M. Caserta N. Bahamondes L. Petta C.A. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging.Contraception. 2007; 76: 195-199Abstract Full Text Full Text PDF PubMed Scopus (99) Google Scholar). Because the treatment of choice for adenomyosis is hysterectomy, when a woman's uterus or her dream of having a family is at stake it seems a rather obvious choice whether to have a hysterectomy or to undergo a promising drug treatment at the expense of prolonging her menstrual cycle. Without any evidence, Drs. Chandrareddy and Muneyyirchi-Delale speculated that the disappearance of pain in the VPA-treated women could very well be “the result of hyperandrogenism and resultant anovulatory cycles induced by VPA [sic],” even though the serum T (testosterone) levels were all normal in our study (1Liu X. Guo S.W. A pilot study on the off-label use of valproic acid to treat adenomyosis.Fertil Steril. 2008; 89: 246-250Abstract Full Text Full Text PDF PubMed Scopus (55) Google Scholar). Our published and unpublished data indicate otherwise (3Wu Y. Guo S.W. Suppression of IL-1beta–induced COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells.Eur J Obstet Gynecol Reprod Biol. 2007; 135: 88-93Abstract Full Text Full Text PDF PubMed Scopus (51) Google Scholar, 4Wu Y. Guo S.W. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells.Eur J Obstet Gynecol Reprod Biol. 2008; 137: 198-203Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar, 5Wu Y. Starzinski-Powitz A. Guo S.W. Trichostatin A. a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells.Reprod Sci. 2007; 14: 374-382Crossref PubMed Scopus (83) Google Scholar). Drs. Chandrareddy and Muneyyirchi-Delale suggested that pretreatment T levels should have been measured, but even if we had done so, the small sample size would have precluded any meaningful comparison. Drs. Chandrareddy and Muneyyirchi-Delale suggest that the patients in our study are more likely to have endometriosis rather than adenomyosis. This assertion is rather strange, because our examinations clearly indicated that all three patients had adenomyosis. Endometriosis may well have coexisted with adenomyosis (6Kunz G. Beil D. Huppert P. Noe M. Kissler S. Leyendecker G. Adenomyosis in endometriosis—prevalence and impact on fertility. Evidence from magnetic resonance imaging.Hum Reprod. 2005; 20: 2309-2316Crossref PubMed Scopus (305) Google Scholar), but whether or not endometriosis coexisted is irrelevant, because our studies have shown the potential of using histone deacetylase inhibitors (HDACIs) to treat endometriosis (3Wu Y. Guo S.W. Suppression of IL-1beta–induced COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells.Eur J Obstet Gynecol Reprod Biol. 2007; 135: 88-93Abstract Full Text Full Text PDF PubMed Scopus (51) Google Scholar, 4Wu Y. Guo S.W. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells.Eur J Obstet Gynecol Reprod Biol. 2008; 137: 198-203Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar, 5Wu Y. Starzinski-Powitz A. Guo S.W. Trichostatin A. a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells.Reprod Sci. 2007; 14: 374-382Crossref PubMed Scopus (83) Google Scholar), which motivated our study in the first place (1Liu X. Guo S.W. A pilot study on the off-label use of valproic acid to treat adenomyosis.Fertil Steril. 2008; 89: 246-250Abstract Full Text Full Text PDF PubMed Scopus (55) Google Scholar). Finally, Drs. Chandrareddy and Muneyyirchi-Delale cited a study (2Bragheto A.M. Caserta N. Bahamondes L. Petta C.A. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging.Contraception. 2007; 76: 195-199Abstract Full Text Full Text PDF PubMed Scopus (99) Google Scholar), published 6 months after our paper (1Liu X. Guo S.W. A pilot study on the off-label use of valproic acid to treat adenomyosis.Fertil Steril. 2008; 89: 246-250Abstract Full Text Full Text PDF PubMed Scopus (55) Google Scholar) was published online, and questioned our statement about the efficacy of progestogenic agents in treating adenomyosis. That study, however, showed no change in the uterine volume, potting occurred in one-third of the women, and oligomenorrhea was common (2Bragheto A.M. Caserta N. Bahamondes L. Petta C.A. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging.Contraception. 2007; 76: 195-199Abstract Full Text Full Text PDF PubMed Scopus (99) Google Scholar). Most importantly, that study is a short-term observational one, not a randomized clinical trial. Therefore, the evidence presented (2Bragheto A.M. Caserta N. Bahamondes L. Petta C.A. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging.Contraception. 2007; 76: 195-199Abstract Full Text Full Text PDF PubMed Scopus (99) Google Scholar) is far from as certain as Drs. Chandrareddy and Muneyyirchi-Delale believe. Any medication has, more or less, side effects, and VPA is no exception. The decision to take a medication or not depends on the careful tradeoff between benefit and risk. Whether VPA is associated with an unacceptable risk if used for treating adenomyosis should be carefully evaluated in future studies. Even if it did, we still should keep in mind that VPA is just one of many HDACIs and that some novel HDACIs may still hold the promise of being more efficacious while having fewer side effects. Risks versus benefits of valproic acid?Fertility and SterilityVol. 90Issue 1PreviewTo the Editor: Full-Text PDF